Diligence memo · auto-generated · as of July 2, 2026
Response Pharmaceuticals, Inc.
Response Pharmaceuticals, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Response Pharmaceuticals, Inc. operates in Pharmaceuticals, based in FALLS CHURCH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Response Pharmaceuticals, Inc. has raised $12M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.0M on 2022-02-08.
Most recent recorded round closed around 2024-06-13.
Valuation (modeled)modeled
Provath models Response Pharmaceuticals, Inc. at approximately $21M (range $4.5M–$45M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.63× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 57% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 28% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.